| Product Name | EBV VCA and EBNA IgG combo rapid assay kit |
| Catalog No. | CA-00184 |
| Description | The EBV VCA and EBNA IgG combo rapid assay kit is a diagnostic tool used to quickly detect the presence of EBV VCA and EBNA IgG in humans. |
| Application | This product can be used for rapid in vitro screening of EBV VCA and EBNA IgG. |
| Operating Temperature | Store at 4-30°C. |
| Transportation Condition | Transportation at room temperature. |
| Background | Epstein-Barr Virus (EBV), a member of the herpesvirus family, is one of the most common human pathogens worldwide. It is estimated that over 90% of adults globally have been infected with EBV by the age of 40. EBV infection can lead to a variety of clinical manifestations, ranging from asymptomatic infection to acute infectious mononucleosis (commonly known as "kissing disease"), and in some cases, it may also be associated with the development of certain malignancies such as nasopharyngeal carcinoma (NPC) and Burkitt's lymphoma. The detection of specific antibodies against EBV is a key method for diagnosing EBV infection and assessing the stage of infection. The EBV VCA and EBNA IgG Combo Rapid Assay Kit (also referred to as EBV VCA/EBNA IgG Dual Rapid Test Kit or EBV Antibody Combo Rapid Detection Kit) targets two crucial EBV-related antibodies: Viral Capsid Antigen (VCA) IgG and Epstein-Barr Nuclear Antigen (EBNA) IgG. ·VCA IgG: This antibody appears relatively early after EBV infection, usually within 2-4 weeks. Its presence indicates a current or past EBV infection. However, since VCA IgG can persist in the human body for a long time (even for life) after infection, a positive result alone cannot accurately distinguish between recent and past infections. ·EBNA IgG: Unlike VCA IgG, EBNA IgG develops later in the course of EBV infection, typically 2-6 months after the initial infection, and also persists for life. The presence of EBNA IgG is a strong indicator of a past EBV infection. If a patient tests positive for VCA IgG but negative for EBNA IgG, it often suggests a recent or acute EBV infection. In clinical practice, the combined detection of VCA IgG and EBNA IgG is of great significance. It not only helps clinicians confirm whether a patient has been infected with EBV but also provides important clues for judging the stage of infection, which is essential for formulating appropriate treatment plans and conducting prognostic evaluations. For example, in patients with symptoms such as fever, sore throat, and lymphadenopathy, the results of this combo assay can help distinguish between acute EBV infection and other diseases with similar symptoms, avoiding misdiagnosis and delayed treatment. |
| Product Features | Dual Target Detection: Simultaneously detects two key antibodies (EBV VCA IgG and EBNA IgG) in a single test, providing comprehensive information about the patient's EBV infection status, which is more efficient than single-antibody detection kits. Rapid Results: Delivers test results within 15-20 minutes, significantly reducing the waiting time for patients and clinicians, and enabling timely clinical decision-making. This is particularly valuable in busy clinical settings such as emergency departments and primary care clinics. User-Friendly Operation: The kit is designed with a simple and intuitive operation process. It does not require complex laboratory equipment or professional technical training, allowing even non-laboratory personnel to perform the test correctly after a short period of guidance. Stable Performance: Maintains stable detection performance within a wide storage temperature range (4-30°C). There is no need for strict cold chain storage during transportation (can be transported at room temperature), which reduces transportation costs and the risk of performance degradation due to improper temperature control. High Sensitivity and Specificity: Utilizes advanced immunochromatographic technology and high-quality antibodies, ensuring high sensitivity (≥98%) and specificity (≥97%) of the test results. This minimizes the occurrence of false-positive and false-negative results, providing reliable diagnostic support for clinicians. |
| Product Advantages | Time-Efficient: Quick results enable prompt diagnosis and treatment decisions, which is crucial in managing EBV infections. Cost-Effective: The combo test reduces the need for multiple diagnostic procedures, lowering overall costs. User-Friendly: Designed for ease of use, allowing healthcare professionals with minimal training to perform the test. Versatile Sample Types: Compatible with whole blood, serum, or plasma samples. Reliable Performance: High sensitivity and specificity ensure accurate detection of EBV antibodies, aiding in differential diagnosis. |
| Related Products | We offer a range of diagnostic kits for other infectious diseases, including the Influenza A&B Rapid Test Kit, Parainfluenza Virus Rapid Test Kit, and the Coronavirus Rapid Test Kit. These kits are designed to provide rapid and accurate detection of specific pathogens, supporting comprehensive infectious disease management. If you are interested in any of these related products or require customized solutions, please feel free to contact us directly. |
For in vitro diagnostic use.
|
There is no product in your cart. |
Copyright © 2025 Alta DiagenoTech. All rights reserved.
